MY ACCOUNT | NEWSLETTER |

MYOS CORP will present three new products, two clinical studies, and the Vet Advisory Board at the VMX 2021 in Orlando

MYOS CORP, a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today that it will be attending in-person the 2021 North American Veterinary Meeting & Expo (VMX) being held June 5-9 in O


The Company will provide industry leaders with updates on three new products within its MYOS Pet line of pet supplements, two new successful clinical studies, and the recent formation of MYOS' Veterinary Advisory Board. 

The VMX Conference provides the animal health industry with an opportunity to learn about innovative, state-of-the-art products and services, in addition to obtaining continuing education (CE) certification in broad areas within Veterinary Medicine. 

"Our team is very excited to be returning in person for another terrific VMX show," said MYOS CEO Joe Mannello. "We've found this event to be a great place to meet with partners, both existing and potential, to share what's new with our company and also learn about industry trends. We've made significant strides in growing our animal health business over the last year, so we'll have lots to share at the event."


New products

MYOS Canine Muscle Formula with Green Lipped Mussel: This new product will feature Fortetropin and Green Lipped Mussel blend. Green Lipped Mussel (GLM) is a shellfish that is native to New Zealand. GLM is a rich source of glycosaminoglycans (GAGs) such as chondroitin sulfate that is a necessary component for cartilage repair. GLM is an abundant source of omega-3 fatty acids such as DHA, EPA, and ETA that suppress inflammation.

Feline Muscle Formula: MYOS Feline Muscle Health Formula comprises 100% Fortetropin, a natural product manufactured from fertilized chicken egg yolk via a patented, low-temperature manufacturing process. Fortetropin is safe and well-tolerated in cats and has been shown to promote the growth and development of muscle tissue in both humans and dogs.

MYOS Muscle & Mobility Collagen Chews: To promote joint health, these chews contain collagen and glucosamine. Branched-chain amino acids are added to promote muscle growth. Both turmeric and blueberry extract is added to suppress inflammation.

New clinical studies

Kansas State University Geriatric study: In a randomized, double-blind, placebo-controlled study, it was observed that dogs that consumed Fortetropin daily experienced statistically significant decreases in LOAD (Liverpool Osteoarthritis in Dogs) scores after 6 weeks of supplementation. Developed by Veterinary Researchers at the University of Liverpool, the LOAD Score is a clinical metrology instrument commonly used to assess the quality of life and mobility of a geriatric dog based on responses to 13 questions.

University of Florida Feline study: Professor Chen Gilor, University of Florida, reported that Fortetropin was safe and well-tolerated in cats at doses ranging from 1 g/day to 4 g/day. This research will be presented at the American College of Veterinary Internal Medicine (ACVIM) Forum in June 2021.

Formation of Veterinary Advisory Board

The MYOS Veterinary Advisory Board comprises leading Veterinarians from Private Practice and U.S. Veterinary Colleges such as the University of Florida, Purdue University, and North Carolina State University, with expertise in areas such as Veterinary Nutrition Canine Osteoarthritis and Chronic Kidney Disease.

About MYOS CORP

MYOS CORP is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity.

For more information, please visit www.myoscorp.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Research on key host pathways has implications for Ebola and beyond

Like0
Dislike0

Anatomical classification of feline extrahepatic portosystemic shunts

Like0
Dislike0

The role of endoscopy in bovine internal medicine

Like0
Dislike0

Use of levetiracetam for the treatment of myoclonic seizures in dogs

Like0
Dislike0

Correlation

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2024 - All Rights Reserved
ISSN 2768-198X

Top